迈威生物：与齐鲁制药就注射用阿格司亭α签署新药项目技术许可协议

Core Viewpoint - Maiwei Biotech has signed a new drug project technology licensing agreement with Qilu Pharmaceutical for the injectable drug Agresten α, which includes exclusive rights for development, production, improvement, utilization, and commercialization in Greater China [1] Group 1: Licensing Agreement Details - The agreement grants Maiwei Biotech exclusive licensing rights for Agresten α in Greater China, which encompasses mainland China, Hong Kong, Macau, and Taiwan [1] - The total payment and sales milestones can reach up to 500 million RMB, including a non-refundable upfront payment of 380 million RMB [1] - The licensing agreement also includes royalties based on net sales of the licensed product, which can reach a maximum of double-digit percentages [1] Group 2: Product Information - Agresten α, also known as Mai Li Sheng®, is a next-generation long-acting G-CSF (Granulocyte Colony-Stimulating Factor) developed by Maiwei Biotech [1] - The product utilizes gene fusion technology to combine high-activity modified G-CSF with human serum albumin (HSA) [1] - It is noted as the first drug in China approved for marketing that employs albumin long-acting fusion technology [1]